UroGen director exercises 2,000 RSUs for shares

UroGen Pharma Ltd. (URGN) director James A. Robinson Jr. reported the exercise and settlement of equity awards.

Rhea-AI Filing Summary

UroGen Pharma Ltd. (URGN) director James A. Robinson Jr. reported the exercise and settlement of equity awards. On 2026-08-26, he exercised 2,000 Restricted Stock Units, each representing a contingent right to receive one ordinary share, which converted into 2,000 ordinary shares of UroGen.

The derivative RSU position of 2,000 units was fully settled, leaving no RSUs from this award outstanding, and Mr. Robinson’s directly held ordinary shares increased to 8,000 shares following the transaction.

Insider Trade Summary

2,000 shares exercised/converted

Exercise 2 txns

Insider Robinson James A. Jr.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F1	2,000	$0.00	$0.00
Exercise	ordinary shares F1	2,000	--	--

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); ordinary shares — 8,000 shares (Direct)

Footnotes (1)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

Key Figures

RSUs exercised: 2,000 units Ordinary shares acquired: 2,000 shares Ordinary shares held after transaction: 8,000 shares +2 more

5 metrics

RSUs exercised 2,000 units Restricted Stock Units exercised and converted on 2026-08-26

Ordinary shares acquired 2,000 shares Ordinary shares received upon RSU exercise on 2026-08-26

Ordinary shares held after transaction 8,000 shares Directly held by James A. Robinson Jr. following the 2026-08-26 transactions

Derivative exercises in filing 1 transaction Exercise or conversion of derivative security reported in transactionSummary

Derivative shares exercised 2,000 shares ExerciseShares in transactionSummary for derivative security exercises

Key Terms

Restricted Stock Unit, derivative security, ordinary shares

3 terms

Restricted Stock Unit financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

derivative security financial

"transaction_action": "derivative exercise/conversion" and transaction_type": "derivative""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

ordinary shares financial

"underlying_security_title": "Ordinary Shares" and security_title": "ordinary shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did URGN director James A. Robinson Jr. report?

He reported exercising 2,000 Restricted Stock Units on 2026-08-26, which converted into 2,000 ordinary shares of UroGen Pharma Ltd., increasing his directly held ordinary share position to 8,000 shares after the transaction.

Did the URGN Form 4 show a sale of shares by James A. Robinson Jr.?

No. The Form 4 shows an exercise or conversion of derivative securities (2,000 RSUs) into 2,000 ordinary shares. There is no reported market sale code; the transaction is recorded as a derivative exercise/conversion and acquisition of ordinary shares.

How many UroGen Pharma (URGN) RSUs did James A. Robinson Jr. settle?

He settled 2,000 Restricted Stock Units. Each RSU represented a contingent right to receive one ordinary share of UroGen Pharma Ltd., resulting in the issuance of 2,000 ordinary shares upon exercise on 2026-08-26.

What are James A. Robinson Jr.’s URGN ordinary share holdings after this Form 4?

After the reported transactions, James A. Robinson Jr. directly holds 8,000 ordinary shares of UroGen Pharma Ltd., as stated in the post-transaction holdings field for the non-derivative ordinary share entry.

What does each URGN Restricted Stock Unit represent in this Form 4?

Each Restricted Stock Unit (RSU) represents a contingent right to receive one ordinary share of UroGen Pharma Ltd., as described in the footnote attached to the RSU transaction in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:02 PM EDT Accepted by SEC EDGAR 08/28/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson James A. Jr.

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ordinary shares	08/26/2026		M		2,000	A	(1)	8,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/26/2026		M			2,000	(1)	(1)	Ordinary Shares	2,000	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

	/s/ Jason D. Smith, Attorney-in-Fact	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)